Apixaban: A new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation

Cardiology in Review

Volumn 21, Issue 4, 2013, Pages 207-212

  Lam, Sum ^a,b  

^a ST JOHN'S UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

antithrombotic agent; apixaban; atrial fibrillation; factor Xa inhibitor; stroke prevention; thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CLARITHROMYCIN; CYTOCHROME P450 3A4; DABIGATRAN; FIBRINOLYTIC AGENT; HEPARIN; ITRACONAZOLE; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; RITONAVIR; RIVAROXABAN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; WARFARIN;

ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG INDICATION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY CLEARANCE; LIFE EXPECTANCY; MORTALITY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE AGGREGATION;

ADMINISTRATION, ORAL; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FIBRINOLYTIC AGENTS; HALF-LIFE; HUMANS; PYRAZOLES; PYRIDONES; RISK FACTORS; STROKE;

EID: 84880136439     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318293d6e6     Document Type: Article

References (27)

1. A merican Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2013 Update: A Report from the American Heart Association. Circulation. 2013;127:e6-e245.
2. W ann LS, Curtis AB, January CT, et al; 2011 Writing Group Members; 2006 Writing Committee Members; ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:104-123.
3. P enado S, Cano M, Acha O, et al. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med. 2003;114:206-210.
4. Baczek VL, Chen WT, Kluger J, et al. Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam Pract. 2012;13:5.
5. Bussey HI. Ximelagatran (Exanta) not recommended by FDA advisory panel, causes MIs? Clotcare Online Resources. Available at: http://clotcare. com/exantanotrecommended.aspx. Assessed March 8, 2013.
6. Frishman WH, Lerner RG, Desai H. Antiplatelet and antithrombotic drugs. In: Frishman WH, Sica DA , eds. Cardiovascular Pharmacotherapeutics. 3rd ed. Minneapolis, MN: Cardiotext; 2011:257-304.
7. Clayville LR, Anderson KV, Miller SA, et al. New options in anticoagulation for the prevention of venous thromboembolism and stroke. P T. 2011;36:86-99.
8. P roduct Information: Eliquis Oral Tablets, Apixaban Oral Tablets. Bristol- Myers Squibb Company, Princeton, New Jersey, 2012.
9. Nutescu E. Apixaban: a novel oral inhibitor of factor Xa. Am J Health Syst Pharm. 2012;69:1113-1126.
10. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594-604.
11. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised doubleblind trial. Lancet. 2010;375:807-15.
12. Lassen MR, Gallus A, Raskob GE, et al; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487-2498.
13. E uropean Medications Agency. Eliquis (apixaban). Available at: http:// www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/ 002148/WC500107728.pdf. Assessed March 6, 2013.
14. Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.
15. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
16. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
17. P atel MR, Mahaffey KW, Garg J, et al; ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
18. D iener HC, Eikelboom J, Connolly SJ, et al; AVERROES Steering Committee and Investigators. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012;11:225-231.
19. E ikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012;21:429-435.
20. E aston JD, Lopes RD, Bahit MC, et al; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11:503-511.
21. Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012;380:1749-1758.
22. A lexander JH, Lopes RD, James S, et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699-708.
23. T herapeutic Research Center. Comparison of oral antithrombotics. Pharmacist's Letter/Prescriber's Letter. February 2013. PL detailed-document #290201.
24. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost. 2012;108:476-484.
25. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167-2177.
26. A MPLIFY (CV185-056) study, Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism. Available at: http://trialresultscenter.org/study10328-AMPLIFY-(CV185-056).htm. Accessed March 14, 2013.
27. A gnelli G, Buller HR, Cohen A, et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368: 699-708.